loading

なぜAclaris Therapeutics Inc(ACRS)の株価が下がっていますか?

2025-05-21 の取引セッション中に、Aclaris Therapeutics Inc (ACRS) 株の 5.19% 下落を確認しました。これは通常のボラティリティやさまざまな内部および外部要因に起因する可能性がありますが、当社では状況を積極的に監視しており、できるだけ早くタイムリーな最新情報を提供することに注意してください。
2023-11-13:

Aclaris Therapeutics Stock (ACRS) dropped by 86.44% from $4.755 to $0.6449 in the trading on Monday November 13, 2023. The reason why ACRS stock down today is due to topline results from a Phase 2b study of zunsemetinib (ATI-450) in subjects with moderate to severe rheumatoid arthritis.

  • Citing topline data at 12 weeks, patients who received either 20mg or 50mg doses of oral zunsemetinib didn’t meet the main endpoint called ACR20 or any secondary endpoints.
  • Based on the overall program results, Aclaris will discontinue further development of the ATI-450 program, including halting enrollment of Aclaris' ongoing Phase 2a trial of zunsemetinib in psoriatic arthritis.
$1.15
price down icon 17.27%
$31.32
price down icon 3.63%
$587.61
price up icon 1.06%
$289.96
price up icon 0.33%
$4.25
price up icon 0.48%
$75.06
price up icon 3.26%
大文字化:     |  ボリューム (24 時間):